Long‐term outcome of non‐fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab

Bouguen, Guillaume; Trouilloud, Isabelle; Siproudhis, L.; Oussalah, Abderrahim; Bigard, Marc‐André; Bretagne, Jean–François; Peyrin–Biroulet, Laurent

doi:10.1111/j.1365-2036.2009.04089.x

Cited by 57 publications

(44 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, neither baseline or cavitating ulcers. 25 In both, combination therapy with IFX and an immunomodulator for patients na€ ıve to immunomodulators appeared as an independent predictive factor of response. Although our rate of combination therapy was similar to theirs (75% and 83% respectively), the majority of our patients had been previously treated by immunomodulators: 77% compared to 33% in their study.…”

Section: Discussionmentioning

confidence: 99%

Predictors of response to infliximab in paediatric perianal Crohn's disease

Dupont-Lucas

Dabadie

Alberti

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of response to infliximab in paediatric perianal Crohn's disease

Dupont-Lucas

Dabadie

Alberti

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Studies, which investigated the results of combined seton and anti-TNF treatment for PFCD, reported a great range of complete response rate between 18-75% (Table IV) [11,12,[15][16][17][18][19][20][21][22][23][24]. Table IV was meticulously prepared only for PFCD.…”

Section: Discussionmentioning

confidence: 99%

Seton drainage combined with anti-tnf therapy for perianal fistulizing Crohn’s disease, single center experience

Yardimci¹,

Kara²,

Attaallah³

et al. 2016

MMJ

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of combined treatment with anti-tumor necrosis factor (TNF) agents, and setons for perianal fistulas in Crohn's disease.Patients and Methods: Study included 27 consecutive patients with perianal fistulizing Crohn's disease, requiring seton drainage and anti-TNF therapy in our center from January 2013 to November 2014. All patients underwent a standardized pelvic magnetic resonance imaging (MRI) examination. Patient characteristics, follow up time, findings of pelvic MRI, colonoscopy and examination under anesthesia findings were recorded. Response to treatment was evaluated at the end of the follow up. Results:The median follow-up after treatment was 17 months (6-32). The fistula was complex in 24 (89%) of the 27 patients. Colonoscopy revealed ileitis in 16 (59.3%) patients and active proctitis in 9 (33.3%) patients. Perianal abscess was observed in 12 (44.4%) patients. Complete response was obtained in 17 (63%) patients. Only 3 (11.1%) patients experienced recurrence abscess during the study period. We could not find any factor, which were associated with complete response. Conclusion:Complete response was achieved in 63% of the patients, with perianal fistula formation associated with Crohn's disease, with combined seton drainage and anti-TNF therapy.

show abstract

“…9 It has been recently shown that patients suffering from nonfistulizing perianal CD may develop anal abscesses under treatment with infliximab. 8,10 But our patient did not suffer from perianal disease in the first appearance of the disease, and perianal disease appeared when she was under treatment with infliximab (and under sustained remission). This type of complication is quite surprising.…”

mentioning

confidence: 89%

Onset of severe perianal disease in Crohnʼs disease under treatment with infliximab

Tursi

Papa

Maiorano

2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Long‐term outcome of non‐fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab

Abstract: SUMMARY BackgroundIn Crohn's disease, anal ulcers and stricture can be disabling.

Cited by 57 publications

References 31 publications

Predictors of response to infliximab in paediatric perianal Crohn's disease

Predictors of response to infliximab in paediatric perianal Crohn's disease

Seton drainage combined with anti-tnf therapy for perianal fistulizing Crohn’s disease, single center experience

Onset of severe perianal disease in Crohnʼs disease under treatment with infliximab

Contact Info

Product

Resources

About